*Emgality is indicated for the prophylaxis of migraine in adults.
European regulation: This medicinal product is subject to additional monitoring. Reporting any suspected adverse reactions associated to this medicine is important
PP-GZ-CH-0140, PP-GZ-GB-0041, PP-GZ-AU-0071
PP-GZ-GB-0037 January 2020, PP-GZ-CH-0146/02.2020
This webinar has been developed, organised and funded by Eli Lilly and Company Ltd. Intended for Healthcare Professionals only. Lilly products will be discussed at this meeting